Two Aryl Rings Or Aryl Ring Systems Bonded Directly To The Same Acyclic Carbon Patents (Class 514/648)
-
Patent number: 8475804Abstract: The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal.Type: GrantFiled: February 22, 2010Date of Patent: July 2, 2013Assignees: U.S. Army Medical Research and Material Command, Zalicus, Inc.Inventors: Lisa M. Johansen, Joseph Lehár, Benjamin G. Hoffstrom, Gene G. Olinger, Andrea R. Stossel
-
Patent number: 8470864Abstract: Disclosed herein are pharmaceutical compositions comprising oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.Type: GrantFiled: February 22, 2010Date of Patent: June 25, 2013Assignee: Theravida, Inc.Inventor: Mehdi Paborji
-
Patent number: 8461389Abstract: The invention provides a selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand for use in the treatment of symptoms of anxiety and/or depression associated with an affective disorder and/or symptoms associated with cognitive impairment disorder. Particularly useful are diphenhydramine derivatives of Formula (I) and particularly (2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethyl-ethanamin) (Captodiamine).Type: GrantFiled: April 20, 2009Date of Patent: June 11, 2013Assignee: University College Dublin, National University of Ireland, DublinInventors: Ciaran Regan, Lisa Conboy, Shane Gannon
-
Publication number: 20130142845Abstract: The present invention is concerned with the use of combinations of opioid agonists and antagonists for treating Crohn's disease.Type: ApplicationFiled: January 30, 2013Publication date: June 6, 2013Applicant: Euro-Celtique S.A.Inventor: Euro-Celtique S.A.
-
Patent number: 8436195Abstract: The use of malachite green in the form of a tetramethyldiamino-triphenyl-carbinol anhydro-oxalate [(C23H25N2)—(C2HO4)]2—C2H2O4 of the following structural formula as a drug for treating malignant neoplasms administered in a single dose of 1 to 2 g. Malachite green can be used when dissolved in an aqueous solution or in a physiological salt solution or in spirit. In different cases, the malachite green solution is perorally administered before and after a meal or is injected per rectum, or a 1% malachite green solution is intravenously introduced, or the malachite green is applied as a rectal suppository component or as a component of 1-5% ointment. The medicinal agent exhibits an extended range of therapeutic actions with respect to different oncological diseases, is freely available, not expensive, non-toxic, does not generate side effects when used in pharmaceutically acceptable doses, and makes it possible to reduce a treating time and to increase the efficiency of treatment.Type: GrantFiled: November 29, 2006Date of Patent: May 7, 2013Inventor: Mikhail Vladimirovich Kutushov
-
Publication number: 20130085183Abstract: Aromatic butan-2-ol compounds, preparation methods for making the compounds, and uses of the compounds are provided. Specifically, the compound of Formula I, or an optical isomer, racemate, diastereomer, pharmaceutically acceptable salt, or solvate thereof, is provided, where each of the substituents is defined. In addition, a pharmaceutical composition containing the compound, and the use of the compound in manufacture of a medicament for the treatment and/or prophylaxis of a disease or disorder caused by tubercle bacillus infection, is provided.Type: ApplicationFiled: May 16, 2011Publication date: April 4, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Ping Liu, Junhai Xiao, Zhibing Zheng, Yunde Xie, Guoming Zhao, Xiaokui Wang, Lili Wang, Xingzhou Li, Xinbo Zhou
-
Publication number: 20130072475Abstract: This disclosure provides methods for treating asthma or an associated disorder in a patient in need thereof, by administering to the patient an effective amount of an autophagy inducing agent, thereby treating the asthma or the associated disorder. Disorders that can be treated include, allergic asthma, chronic obstructive pulmonary disease, lung inflammation, respiratory tolerance and a lung infection or disorder.Type: ApplicationFiled: August 2, 2012Publication date: March 21, 2013Inventor: Omid Akbari
-
Publication number: 20130053400Abstract: The invention provides antihistamine drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the antihistamine drug not attached to the water-soluble oligomer.Type: ApplicationFiled: September 7, 2012Publication date: February 28, 2013Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Wen Zhang, Tacey X. Viegas, Michael D. Bentley
-
Publication number: 20130045956Abstract: The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be provided. The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be safely administered to the patients with Hand-Foot Syndrome, and has shown the superior preventive and/or treatment effect against Hand-Foot Syndrome.Type: ApplicationFiled: March 30, 2011Publication date: February 21, 2013Inventors: Kazuhiro Ishizaka, Tadashi Nomizu, Aya Kitao
-
Publication number: 20130046025Abstract: Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises at least one essential oil as an abirritant to minimize skin irritation caused by tolterodine. The composition relieves skin irritation caused by tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.Type: ApplicationFiled: February 17, 2011Publication date: February 21, 2013Applicant: SK Chemicals Co., Ltd.Inventors: Yong Youn Hwang, Won-Jae Choi, Jae-Sun Kim, Yeo-Jin Park, Joon-Gyo Oh, Bong-Yong Lee, Hae-In Rhee, Jong-Seob Im
-
Publication number: 20130046026Abstract: Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises lidocaine or a pharmaceutically acceptable salt thereof to achieve enhanced skin penetration. The composition enhances the skin penetration of tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.Type: ApplicationFiled: February 17, 2011Publication date: February 21, 2013Applicant: SK CHEMICALS CO., LTD.Inventors: Yong Youn Hwang, Won-Jae Choi, Jae-Sun Kim, Yeo-Jin Park, Joon-Gyo Oh, Bong-Yong Lee, Hae-In Rhee, Jong-Seob Im
-
Patent number: 8376140Abstract: A vehicle to carry a powered medication that addresses the limitations of the prior art. It includes a system and method. A powder delivery system includes a first panel and a second panel coupled together around a periphery of the panels to form a sealed void therebetween, each the panel having a width and length about equal to a standard credit card width and length, respectively; and a powder, disposed in the void, having a quantity at least about equal to an active dose of the powder; wherein a thickness of the panels with the powder disposed therebetween is not greater than about 0.1 inches and more preferably not greater than about 0.03 inches.Type: GrantFiled: April 20, 2009Date of Patent: February 19, 2013Assignee: Breakthrough Products, Inc.Inventor: Jordan Eisenberg
-
Publication number: 20130023488Abstract: Compounds and compositions for reducing intracellular lipid accumulation in a cell are described herein. These compounds are useful for the treatment and prevention of lipid/glycogen disorders, as well as for the treatment and prevention of obesity. A high throughput screen for identifying compounds that reduce intracellular lipid accumulation in cells is also provided.Type: ApplicationFiled: July 19, 2012Publication date: January 24, 2013Applicant: The General Hospital CorporationInventor: Sean Wu
-
Patent number: 8349899Abstract: Embodiments of the present invention comprises a compound of formula I or its enantiomer, diastereomer, stereoisomer or its pharmaceutically acceptable salt, methods of use and methods of synthesis.Type: GrantFiled: December 3, 2009Date of Patent: January 8, 2013Assignee: Arrowhead Center, Inc.Inventors: Jeffrey Arterburn, Charles Shuster
-
Publication number: 20120322761Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.Type: ApplicationFiled: August 29, 2012Publication date: December 20, 2012Inventors: Mark E. Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Jianqing Li, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
-
Publication number: 20120309839Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass. limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility.Type: ApplicationFiled: August 20, 2012Publication date: December 6, 2012Applicant: REPROS THERAPEUTICS INC.Inventor: Joseph S. Podolski
-
Patent number: 8318699Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.Type: GrantFiled: January 31, 2006Date of Patent: November 27, 2012Assignees: The Trustees Of The University Of Pennsylvania, Cephalon, Inc.Inventors: Mark I Greene, Ramachandran Murali, Xin Cheng, Raphael Ottenbrite, Yingxin Xiao
-
Publication number: 20120289470Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 15, 2011Publication date: November 15, 2012Inventors: Mark C. HEIT, Antonio M. BENITZ, Dennis F. STEADMAN, David M. PETRICK
-
Publication number: 20120282266Abstract: The invention relates to methods for the prophylaxis and treatment of breast cancer using one or more antagonists of artemin function, such as anti-artemin polynucleotides or anti-artemin antibodies and antibody fragments, and uses of these antagonists. In particular, the invention relates to the resensitisation of therapy-resistance breast cancer cells to anti-cancer therapies by antagonism of artemin functionality.Type: ApplicationFiled: October 15, 2010Publication date: November 8, 2012Applicant: AUCKLAND UNISERVICES LIMITEDInventor: Peter Edward Lobie
-
Publication number: 20120270947Abstract: Disclosed are compositions and methods related to assessing the risk of cancer, such as breast cancer, through analyzing the length of telomeres, such as chromosome 9p telomere, such as the short arm of the 9p telomere. If the 9p arm is shorter than normal, the risk of cancer is increased.Type: ApplicationFiled: October 17, 2011Publication date: October 25, 2012Applicant: Georgetown UniversityInventor: Yun-Ling Zheng
-
Patent number: 8293799Abstract: The osmotic devices of the present invention include a single core comprising a salt of a drug and an osmotic salt, wherein the drug salt and the osmotic salt have a common ion. The release rate of the active drug is reduced, and the release profile of the active drug is modified, from a first order release profile to a zero order, pseudo-zero order, or sigmoidal release profile, by increasing the amount of the sodium chloride in the core of the device. In one embodiment the sodium chloride is used to modify a controlled release profile to a delayed and controlled release profile.Type: GrantFiled: December 13, 2004Date of Patent: October 23, 2012Assignee: Osmotica Keresleedelmo és Szolgáltató KFTInventors: Ethel C. Feleder, Glenn A. Meyer, Marcelo A. Ricci, Joaquina Faour, Ana C. Pastini, Marcelo F. Befumo
-
Publication number: 20120245231Abstract: The present invention is directed toward a method of administering an oral solution containing one or more active ingredients, preferably formulations for non-prescription medicines, vital fluids, and/or nutritional supplements, optimally dosed based upon a patient's weight. The method includes providing an oral solution having an effective amount of one or more active ingredients; determining the weight of the individual, preferably to an individual less than 12 years old; and administrating an appropriate amount of the oral solution in a single dose dispensing unit in accordance with the weight determination of the individual, whereby the total amount of active ingredient administered corresponds to an effective amount of the active ingredient based on the individual's weight.Type: ApplicationFiled: June 6, 2012Publication date: September 27, 2012Inventors: Brian Kaplan, Robert Terwilliger, Richard Haskins
-
Patent number: 8268894Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.Type: GrantFiled: November 11, 2010Date of Patent: September 18, 2012Assignees: The United States of America as Represented by the Secretary, Department of Health and Human Services, Sequella, Inc.Inventors: Marina Nikolaevna Protopopova, Elena Bogatcheva, Leo Einck, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III
-
Publication number: 20120201908Abstract: The disclosure provides methods of treating bipolar disorder by administering an antiestrogen to reduce the severity and frequency of mood episodes. The disclosure further provides methods of treating depression with an antiestrogen in a descending dose protocol.Type: ApplicationFiled: August 12, 2010Publication date: August 9, 2012Applicant: Lunera Equities, LLLPInventor: Kirk Patrick Miller
-
Publication number: 20120178821Abstract: The present invention provides a polymorphic form of toremifene citrate and processes for its preparation. It also relates to an improved process for the preparation of the Z isomer of the toremifene base, free of E isomer, and its pharmaceutically acceptable salts.Type: ApplicationFiled: July 30, 2010Publication date: July 12, 2012Applicant: RANBAXY LABORATORIES LIMITEDInventors: Pranab Chatterjee, Asok Nath, Mohan Prasad
-
Publication number: 20120165360Abstract: The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 5, 2012Publication date: June 28, 2012Applicant: THERAVANCE, INC.Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, Lan Jiang, Sabine Axt
-
Publication number: 20120164075Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases, infectious diseases, fertility disorders, osteoporosis, osteoarthritis, and/or cardiovascular diseases. Specifically, the present invention relates to compositions comprising endoxifen for use in the treatment of such disorders or predisposition to such disorders, for use in manufacture of medicaments for treating such disorders, and methods comprising use of such compositions in such treatments.Type: ApplicationFiled: May 21, 2010Publication date: June 28, 2012Applicant: JINA PHARMACEUTICALS, INC.Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Publication number: 20120157542Abstract: The present invention is related to a method of classifying a sample of a patient who suffers from or being at risk of developing cancer, said method comprising the steps of determining in said sample from said patient, on a non protein basis, the expression level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample; comparing the one or more expression level(s) determined with one or more expression level(s) of one or more reference genes, and classifying the sample of said patient from the outcome of the comparison into one of at least two classifications.Type: ApplicationFiled: October 28, 2011Publication date: June 21, 2012Inventor: Ralph Wirtz
-
Patent number: 8202910Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. In certain embodiments, the present invention comprises compositions comprising novel substituted ethylene diamine compounds further comprising antitubercular agents such as rifampicin, isoniazid, pyrazinamide and ethambutol.Type: GrantFiled: October 22, 2008Date of Patent: June 19, 2012Assignee: Sequella, Inc.Inventors: Marina Nikolaena Protopopova, Leo Einck, Boris Nikonenko, Ping Chen
-
Publication number: 20120142654Abstract: The invention provides an analytical method for the determination of the susceptibility of a human patient suffering from breast cancer to anti-cancer treatment by providing an analytical method for determining the genetic predisposition of a patient in respect of susceptibility, e.g. responsiveness, to anti-cancer treatment, especially treatment using at least one chemotherapeutical agent and/or at least one anti-hormonal agent on the basis of analysis of a genetic marker.Type: ApplicationFiled: December 6, 2011Publication date: June 7, 2012Applicant: Medizinische Hochschule HannoverInventors: Thilo Doerk-Bousset, Michael Heuser, Frederik Martin Georges Damm, Arnold Ganser, Tjoung-Won Park-Simon, Peter Hillemanns
-
Patent number: 8193391Abstract: A new process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N,alkyl-3-phenylpropylamines from cinnamyl chloride via N-alkyl-3-phenylprop-2-en-1-amine has been developed.Type: GrantFiled: June 18, 2007Date of Patent: June 5, 2012Assignee: Lek Pharmaceuticals, D.D.Inventor: Erik Fischer
-
Publication number: 20120135971Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.Type: ApplicationFiled: January 18, 2012Publication date: May 31, 2012Inventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger
-
Publication number: 20120135073Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.Type: ApplicationFiled: February 3, 2012Publication date: May 31, 2012Inventors: SU IL YUM, Grant Schoenhard, Arthur J. Tipton, John W. Gibson, John C. Middleton
-
Publication number: 20120135072Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.Type: ApplicationFiled: February 3, 2012Publication date: May 31, 2012Inventors: SU IL YUM, Grant Schoenhard, Arthur J. Tipton, John W. Gibson, John C. Middleton
-
Publication number: 20120128766Abstract: Self-breaking core tablets and functionally coated tablets and capsule formulations are provided. Methods for production of these tablet and capsule formulations and their administration are also provided.Type: ApplicationFiled: July 2, 2010Publication date: May 24, 2012Applicant: Aptapharma, Inc.Inventors: Ishwar Chauhan, Siva Rama Krishna Nutalapati
-
Patent number: 8183287Abstract: The present invention provides compositions as well as kits and methods based on a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 that are useful for treating inflammatory disorders.Type: GrantFiled: June 12, 2007Date of Patent: May 22, 2012Assignee: Schering CorporationInventors: Jim H. Kou, Jonathan D. Eichman
-
Publication number: 20120122992Abstract: Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other uses.Type: ApplicationFiled: March 19, 2010Publication date: May 17, 2012Applicant: University of Pittsburgh-Of the Commonwealth SysteInventors: Billy W. Day, Waikok Michael Tsang, Vasiliy N. Korotchenko
-
Publication number: 20120121729Abstract: Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.Type: ApplicationFiled: October 12, 2011Publication date: May 17, 2012Inventors: Blake PATERSON, Mark Ginski, Brendan Canning
-
Publication number: 20120104039Abstract: A system for individual dosing of a medicament, in accordance with the individual pathological properties (“fingerprint”) of a patient—corresponding physiologically or genetically to the disease status is based on two components: the medicament that is to be taken or administered in a variable individual dosage and a miniaturized indicator system that obtains information from blood, saliva or other bodily fluids and tissues of the patient and displays the information in a readable form so that the patient or the treating physician can immediately read the optimal active substance to be taken or dosage to be administered.Type: ApplicationFiled: September 28, 2011Publication date: May 3, 2012Applicant: MCS MICRO CARRIER SYSTEMS GMBHInventors: Hans Schreier, Wolfgang Greb
-
Publication number: 20120093929Abstract: The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.Type: ApplicationFiled: May 5, 2009Publication date: April 19, 2012Applicant: Euro-Celtique S.A.Inventors: Alexander Oksche, Kevin J. Smith, Derek Prater, Malcolm Walden, Will Heath, Bernard Kennedy, Vanessa Addison, Hassan Mohammad
-
Publication number: 20120093938Abstract: The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.Type: ApplicationFiled: July 14, 2011Publication date: April 19, 2012Applicant: EURAND INC.Inventors: Gopi M. VENKATESH, Jin-Wang LAI, Phillip PERCEL, Craig KRAMER
-
Patent number: 8158575Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: GrantFiled: July 6, 2009Date of Patent: April 17, 2012Assignee: Starpharma Pty., LtdInventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
-
Patent number: 8119695Abstract: Disclosed are novel compositions and novel methods for the creation of both the novel compounds and known compounds. Also disclosed are methods for use of the novel compounds for treating a variety of diseases relating to decreasing or preventing activation of estrogen receptors and/or estrogen related receptors.Type: GrantFiled: March 20, 2009Date of Patent: February 21, 2012Assignee: City of HopeInventors: Barry Forman, Donna Yu
-
Publication number: 20120034270Abstract: The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with in-appropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.Type: ApplicationFiled: October 16, 2009Publication date: February 9, 2012Applicant: Akaal Pharma Pty LtdInventors: Damian W. Grobelny, Gurmit S. Gill
-
Patent number: 8101666Abstract: The invention provides methods for detection of medical disorders, associated with cellular oxidative stress, cell degeneration and/or cell death. The invention further relates to compounds comprising a thiol (—SH) group, for detecting cells undergoing oxidative stress, degeneration and/or a death process. The invention further provides methods for utilizing the compounds in medical practice, for diagnostic and therapeutic purposes.Type: GrantFiled: July 7, 2005Date of Patent: January 24, 2012Assignee: Aposense Ltd.Inventors: Ilan Ziv, Anat Shirvan
-
Publication number: 20120010245Abstract: The present invention relates to transdermal pharmaceutical compositions such as gels containing a SERM selected from the group consisting of endoxifen, droloxifene, clomifene, raloxifene, tamoxifen, 4-OH tamoxifen, toremifene, danazol and the pharmaceutically acceptable salts thereof, and to methods of making and using the same.Type: ApplicationFiled: December 9, 2009Publication date: January 12, 2012Inventor: Valerie Masini-Eteve
-
Publication number: 20120003316Abstract: This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of one or more pharmaceutical compositions via the buccal, sublingual, rectal, vaginal or transmucosal delivery route in a human or animal body. It provides for selected delivery profiles resulting from, but not limited to, a porosity-enabled composite matrix of one or more layers/components of the pharmaceutical composition/s. The invention also provides for a method of manufacturing said transmucosal pharmaceutical dosage form in a plurality of configurations.Type: ApplicationFiled: June 3, 2009Publication date: January 5, 2012Inventors: Deshika Reddy, Oluwatoyin Ayotomilola Adeleke, Viness Pillay, Yahya Choonara
-
Publication number: 20110319441Abstract: The present invention features the present invention features a tablet including at least one pharmaceutically active ingredient, wherein the shape of said tablet includes at least one major face wherein: (i) the peak penetration resistance at the perimeter of said major face of the tablet is at least about 10% greater than the peak penetration resistance at the center of said major face; and (ii) the tablet disintegrates in the mouth when placed on the tongue in less than about 30 seconds, and a machine and method for manufacture of such tablet.Type: ApplicationFiled: March 21, 2011Publication date: December 29, 2011Inventors: Christopher E. Szymczak, Frank J. Bunick, Harry S. Sowden, Joseph R. Luber, Leo B. Kriksunov
-
Publication number: 20110318411Abstract: The present invention features a tablet containing a first layer and a second layer, wherein: (i) the first layer includes a pharmaceutically active agent and the composition of the first layer is different from the composition of the second layer; (ii) the tablet has a density less than about 0.8 g/cc; and (iii) the tablet disintegrates in the mouth when placed on the tongue in less than about 30 seconds.Type: ApplicationFiled: March 21, 2011Publication date: December 29, 2011Inventors: Joseph R. Luber, Frank J. Bunick, Harry S. Sowden, Leo B. Kriksunov, Christopher E. Szymczak
-
Publication number: 20110319483Abstract: The present invention relates to the compounds of the general formula (I), a composition for and a method of treating breast cancer or other proliferative disorders in a subject using a compound of general formula [I], wherein the substituents are as defined in the specification.Type: ApplicationFiled: September 2, 2011Publication date: December 29, 2011Inventors: Gloria L. Anderson, Tawfeq Abdul-Raheem Kaimari